GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns

The generic industry should consider carefully any attempt to derail FDA's regulatory approach to Waxman/Hatch reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association